Seeking Alpha

Discovery Labs (DSCO +17.9%) could be acquired, speculates Roth Capital. Following the approval...

Discovery Labs (DSCO +17.9%) could be acquired, speculates Roth Capital. Following the approval of its synthetic surfactant, Surfaxin, by the FDA, Roth says the company could sell itself, or obtain a partner. It raises its target on the shares to $10 from $6 while maintaining its Buy rating.
Comments (3)
  • Begosa
    , contributor
    Comment (1) | Send Message
     
    After two FDA approvals in less than a month and all we it is a 8.80% profit. Isn't it very dissapointing?.
    7 Mar 2012, 10:38 PM Reply Like
  • Jcri7313
    , contributor
    Comment (1) | Send Message
     
    yes very dissapointing
    8 Mar 2012, 11:52 AM Reply Like
  • gcrain
    , contributor
    Comments (85) | Send Message
     
    I'm a buyer and you should be too. Lot's of upside on this one especially when they get bought. King Kong Long . They are on every traders radar screen now.

     

    RX7Turbobirddog.
    8 Mar 2012, 10:30 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs